JP2021512140A5 - - Google Patents
Info
- Publication number
- JP2021512140A5 JP2021512140A5 JP2020558858A JP2020558858A JP2021512140A5 JP 2021512140 A5 JP2021512140 A5 JP 2021512140A5 JP 2020558858 A JP2020558858 A JP 2020558858A JP 2020558858 A JP2020558858 A JP 2020558858A JP 2021512140 A5 JP2021512140 A5 JP 2021512140A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- methoxyquinoline
- ethylpiperazine
- methylureido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023149903A JP7665700B2 (ja) | 2018-01-10 | 2023-09-15 | 肝細胞癌の治療のための併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615848P | 2018-01-10 | 2018-01-10 | |
| US62/615,848 | 2018-01-10 | ||
| PCT/US2019/012886 WO2019139977A1 (en) | 2018-01-10 | 2019-01-09 | Combination therapies for the treatment of hepatocellular carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149903A Division JP7665700B2 (ja) | 2018-01-10 | 2023-09-15 | 肝細胞癌の治療のための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512140A JP2021512140A (ja) | 2021-05-13 |
| JP2021512140A5 true JP2021512140A5 (https=) | 2022-01-18 |
| JP7352569B2 JP7352569B2 (ja) | 2023-09-28 |
Family
ID=65411938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558858A Active JP7352569B2 (ja) | 2018-01-10 | 2019-01-09 | 肝細胞癌の治療のための併用療法 |
| JP2023149903A Active JP7665700B2 (ja) | 2018-01-10 | 2023-09-15 | 肝細胞癌の治療のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149903A Active JP7665700B2 (ja) | 2018-01-10 | 2023-09-15 | 肝細胞癌の治療のための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11833119B2 (https=) |
| EP (2) | EP4667005A3 (https=) |
| JP (2) | JP7352569B2 (https=) |
| KR (2) | KR102811519B1 (https=) |
| CN (1) | CN111787922A (https=) |
| AU (1) | AU2019206480A1 (https=) |
| BR (1) | BR112020014112A2 (https=) |
| CA (1) | CA3088292A1 (https=) |
| IL (1) | IL275981A (https=) |
| MA (1) | MA51570A (https=) |
| MX (1) | MX2020007375A (https=) |
| SG (1) | SG11202006617RA (https=) |
| WO (1) | WO2019139977A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533903A (ja) * | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 |
| JP2025520303A (ja) * | 2022-05-30 | 2025-07-03 | 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 | 癌治療用の医薬組み合わせ物および医薬組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| KR100804566B1 (ko) | 2003-12-25 | 2008-02-20 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법 |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| EP2809312A1 (en) | 2012-01-31 | 2014-12-10 | Novartis AG | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
| BR112015029386B1 (pt) | 2013-06-26 | 2023-11-14 | Eisai R&D Management Co., Ltd. | Uso de eribulina e lenvatinibe como terapia de combinação e kit |
| PH12016500676B1 (en) * | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| HRP20210319T1 (hr) * | 2014-03-26 | 2021-04-30 | Astex Therapeutics Ltd. | Kombinacije inhibitora fgfr i inhibitora igf1r |
| US20160089365A1 (en) | 2014-09-25 | 2016-03-31 | Eisai R&D Management Co., Ltd. | Immunostimulatory compound |
| KR102548229B1 (ko) | 2015-04-14 | 2023-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 결정질 fgfr4 억제제 화합물 및 그의 용도 |
| CN107304188A (zh) | 2016-04-20 | 2017-10-31 | 成都融科博海科技有限公司 | 一种氘代激酶选择性抑制剂及其应用 |
| JP7372740B2 (ja) | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ |
-
2019
- 2019-01-09 MA MA051570A patent/MA51570A/fr unknown
- 2019-01-09 WO PCT/US2019/012886 patent/WO2019139977A1/en not_active Ceased
- 2019-01-09 EP EP25207224.4A patent/EP4667005A3/en active Pending
- 2019-01-09 US US16/961,292 patent/US11833119B2/en active Active
- 2019-01-09 AU AU2019206480A patent/AU2019206480A1/en not_active Abandoned
- 2019-01-09 JP JP2020558858A patent/JP7352569B2/ja active Active
- 2019-01-09 EP EP19705261.6A patent/EP3737377B1/en active Active
- 2019-01-09 MX MX2020007375A patent/MX2020007375A/es unknown
- 2019-01-09 KR KR1020207022999A patent/KR102811519B1/ko active Active
- 2019-01-09 KR KR1020257016389A patent/KR20250073570A/ko active Pending
- 2019-01-09 CA CA3088292A patent/CA3088292A1/en active Pending
- 2019-01-09 CN CN201980015321.XA patent/CN111787922A/zh active Pending
- 2019-01-09 BR BR112020014112-7A patent/BR112020014112A2/pt not_active IP Right Cessation
- 2019-01-09 SG SG11202006617RA patent/SG11202006617RA/en unknown
-
2020
- 2020-07-12 IL IL275981A patent/IL275981A/en unknown
-
2023
- 2023-09-15 JP JP2023149903A patent/JP7665700B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019059760A5 (https=) | ||
| ES2393211T3 (es) | Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor | |
| ES2654787T3 (es) | Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento | |
| JP2004525179A5 (https=) | ||
| JP2012162581A (ja) | 経口治療用化合物の供給系 | |
| JP2004512328A5 (https=) | ||
| JP2021152008A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| WO2002092088A3 (en) | Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts | |
| JP2006508953A5 (https=) | ||
| JP2017528507A5 (https=) | ||
| CY1119663T1 (el) | Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2 | |
| JP2012532874A5 (https=) | ||
| JP2018168191A5 (https=) | ||
| JP2015528471A5 (https=) | ||
| JP2018048154A5 (https=) | ||
| JP2017530983A5 (https=) | ||
| JP2017537899A5 (https=) | ||
| JP2019515909A5 (https=) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2019536812A5 (https=) | ||
| JP2017222722A5 (https=) | ||
| JP2014505107A5 (https=) | ||
| JP2018537507A5 (https=) | ||
| JP2020529995A5 (https=) |